

PATENT CASE IN0115

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Arasappan et al.

Serial No.:09/909,077

Filed: July 19, 2001



Examiner: Not assigned yet

Group Art Unit: Not assigned yet

Atty. Docket No.: IN01156

For: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF

HEPATITIS C VIRUS

Assistant Commissioner for Patents Washington, D.C. 20231

RECEIVED

INFORMATION DISCLOSURE STATEMENT

JAN 1 1 2002

Sir:

GROUP 3600

It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.

Documents cited in the Application:

U.S. 5,712,145

WO 89/04669

WO 98/17679

WO 98/22496

WO 99/07734

WO 00/09558

WO 00/09543

EP 381 216

Publications:

Pizzi et al. (1994) Proc. Natl. Acad. Sci (USA) 91:888-892

Failla et al. (1996) Folding & Design 1:35-42

Kollykhalov et al. (1994) J. Virol. 68:7525-7533

Komoda et al. (1994) J. Virol. 68:7351-7357

Landro et al. (1997) Biochem. 36:9340-9348

Ingallinella et al. (1998) Biochem. 37:8906-8914

Llinàs-Brunet et al. (1998) Bioorg. Med. Chem. Lett. 8:1713-1718

Martin et al. (1998) Biochem. 37:11459-11468

Dimasi et al. (1997) J. Virol. 71:7461-7469

Martin et al. (1997) Protein Eng. 10:607-614

Elzouki et al.) (1997) J. Hepat. 27:42-48

BioWorld Today 9(217): 4 (November 10, 1998)

Berenguer et al. (1998) Proc. Assoc. Am. Physicians 110(2):98-112

Hoofnagle et al. (1997) N. Engl. J. Med. 336:347

R. Zhang et al, Analytical Biochemistry, 270 (1999) 268-275

BEST AVAILABLE COPY



- D. L. Sali et al, Biochemistry, 37 (1998) 3392-3401
- K. Barlos et al, Int. J. Pept. Protein Res., 37 (1991), 513-520
- K. Holmberg et al, Acta Chem. Scand., B33 (1979) 410-412
- A. Marchetti et al, Synlett., S1 (1999) 1000-1002
- W. Han et al, Bioorganic & Biomedicinal Chem Lett., 10 (2000) 711-713
- S. Agrawal et al, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", Hepatology Supplement to Volume 30 (No. 4, Part 2, October 1999), Abstract No. 615 (Proceedings of AASLD 50th Annual Meeting, Dallas, Texas, November 5-9, 1999.
 - L. Hughes, Org. Reactions, 42 (1992) 335.
 - R. F. Heck, Org. Reactions, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001 Schering-Plough Corporation 2000 Galloping Hill Road Patent Department, K-6-1,1990 Kenilworth, NJ 07033

Tel: (908) 298-5068 Fax: (908) 298-5388

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as First Class Mail in an envelope addressed to Assistant Commissioner for Patents, Washington, D.C. 20231 on

December 19, 2001

Palaiyur S. Kalyanaraman

Registered Representative

Signature and Date of Signature

Respectfully submitted,

Palaiyur S. Kalyanaraman

Attorney for Applicants

Reg. No. 34,634

FORM PTO-1449

EXAMINER

AB

INITIAL

J.S. DEPARTMENT OF COMMERCE

PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use several sheets if necessary)

DOCUMENT

NUMBER

AA U.S. 5,712,145

ATTY. DOCKET NO.:	SERIAL NO.:	
IN01156	09/909.077	5
APPLICANT:	<u> </u>	$- \approx$
SAKSENIA atal	8	<u></u>

FILING DATE: GROUP: July 19, 2001 To Be Assigned

U.S. PATENT DOCUMENTS						
DATE	NAME	CLASS		FILING DATE IF APPROPRIATE		
i						

		ļ.	
FOREIGN	PATENT DOCUMENTS		
DATE	COLINTRY	 01.400	61.15

		DOCUMENT	DATE	COUNTRY	CLASS	SUB-	TDANICI	ATION
]		·	J	1000111111	CLASS	į.	TRANSL	
		NUMBER			f	CLASS	YES	NO
	4C	WO 89/04669						
A	۱D	WO 98/17679						
	٩E	WO 98/22496						
1	٩F	WO 98/07734						
P	١G	WO 00/09558						
P	λΗ	WO 00/09543			····			
/	ΑI	EP 381 216						
ļ /	٩J							
P	١K							

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Pizzi,	(1994)	Proc.	Natl.	Acad.	Sci	(USA	91:888	3-892	
ΔM	Failla	(1996)	foldin	0 8 D	ocian	1.25	42			_

Kollykhalov (1994) J. Virol. 68:7525-7533

AO | Komoda (1994) J. Virol. 68:7351-7357 AP | Landro (1997) Biochem 36:9340-9348

AQ | Ingallinella (1998) Biochem 37:8906-8914

AR Llinas-Brunet (1998) Bioorg. Med. Chem. Lett, 8:1713-1718

AS | Martin (1998) Biochem 37:11459-11468 AT Dimasi (1997) J. Virol. 71:7461-7469

Martin (1997) Protein Eng. 10:607-614

AV | Elzouki (1997) J. Hepat. 27:42-48

AW | Bio World Today 9(217): 4 (November 10, 1998)

Berenguer (1998) Proc. Assoc. Am. Physicians 110(2): 98-112

ΑY Hoofnagle (1997) New England Journal Med. 336:347

ΑZ Zhang (199) Analytical Biochemistry 270:268-275 BA

Sali (1998) Biochemistry 3392-3401 BB Barlos (1991) Int. J. Pept. Protein Res 513-520

BC | Holmberg (1979) Acta Chem. Scand., B33:410-412

Agrawal(1999) Hepatology Supplement to Vol 30 "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"

BE Hughes (1992) Org. Reactions 42:335

BF Heck (1989) Org. Reactions 27:345-390

Han, (2000) Bioorganic & Medicinal Chemistry Letters 10 " α -Ketoamides, α -Ketoesters and α -BG Kiketones as HCV NS3 Protease Inhibitors" pp. 711-713.

Marchetti(1999) Synlett, Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an BH Inhibitor of HCV NS3 Protease", pp 1000-1002.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.